Molecs logo

Molecs

We learn from the puzzling nature of genome.

1 employees · est. 2019 · Istanbul

VS
Pathos logo

Pathos

AI-enabled drug development built for patients

96 employees · est. 2022 · Chicago, United States

Molecs is the older company (2019 vs 2022); Pathos is the larger of the two.

Side-by-Side Comparison

Molecs Pathos
Founded
2019 older 2022
Headquarters
Istanbul Chicago, United States
Employees
1 96 larger
Industry
AI, Deep Tech, Enterprise Software Not tracked yet
Funding Stage
Not tracked yet Series D
Total Funding
Not tracked yet $365.00M
Funding Rounds
Not tracked yet 3
Services
Not tracked yet AI-driven Clinical Trials, Precision Therapy Discovery, Data Modeling for Oncology, Biopharmaceutical Collaboration
Target Customers
Not tracked yet Biopharmaceutical Companies, Clinical Researchers, Healthcare Providers, Investors in Biotech
Taxonomy
Genomics, Clinical Analysis, Precision Medicine, Oncology, Decision Support, Cloud Platform, Clinical Genomics, Health Professionals, Molecular Biology, Medical Technology, Data Science AI-enabled Drug Development, Precision Oncology, Multimodal Patient Data, Oncology, Biomarker-driven Clinical Execution, Clinical Trials, Drug Discovery, Cancer Biology, Computational Biology, Biopharma, Model-driven Hypotheses, Precision Medicine
Website
molecs.com pathos.com
Molecs logo

About Molecs

Molecs is a startup that operates in the intersection of AI, Deep Tech, Enterprise Software, Life Sciences, Professional Services Tech, and SaaS. Since its founding in 2019, the company has been dedicated to providing clinical genomics analysis & decision support cloud platforms that cater specifica...

Pathos logo

About Pathos

Pathos, founded in 2022 and headquartered in the United States, is a clinical-stage, AI-enabled precision oncology biotech. Its slogan, "AI-enabled drug development built for patients", encapsulates its mission to revolutionize the biopharma sector. The company is pioneering the integration of AI w...

We will tell you when either one moves

BounceWatch watches Molecs and Pathos for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Molecs and Pathos — by email.

Frequently Asked Questions

Molecs — We learn from the puzzling nature of genome.. Pathos — AI-enabled drug development built for patients. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Molecs has raised undisclosed funding while Pathos has raised $365.00M.
Molecs and Pathos operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Molecs with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Molecs on 11 Sep 2024, and Pathos on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy